1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin.
79 women who had been menopausal for less than 36 months and who had not received any form of treatment to prevent bone loss were randomly assigned to a 12-month regimen of calcium 500 mg/day or calcium 500 mg plus intranasal salmon calcitonin 50 IU/day for 5 days per week. After 12 months of treatment bone mineral density had decreased in the calcium-only group by a mean of 3.16 (SEM 0.6)% (p less than 0.01) but had increased in the calcium plus calcitonin group by 1.38 (0.8)% (NS). The difference in response between the two treatment groups was also highly significant (p less than 0.01), as was the difference between values for hydroxyprolinuria/creatininuria (p less than 0.01). Endogenous calcitonin levels rose significantly in the calcium group but remained unchanged in calcitonin-treated patients. Treatment by calcitonin and calcium was not followed by increased secretion of parathyroid hormone. The findings suggest that intranasal calcitonin can counteract early postmenopausal bone loss.
D000281:Administration, Intranasal; D001842:Bone and Bones / Q000000981:diagnostic imaging; D002116:Calcitonin / Q000008:administration & dosage* / Q000627:therapeutic use; D002118:Calcium / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000652:urine; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008903:Minerals / Q000032:analysis; D010024:Osteoporosis / Q000517:prevention & control*; D011877:Radionuclide Imaging; D011897:Random Allocation; D013607:Tablets / Q000009:adverse effects; D013997:Time Factors
D008903:Minerals; D013607:Tablets; C028815:salmon calcitonin; D002116:Calcitonin; D003404:Creatinine; D006909:Hydroxyproline; D002118:Calcium